Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Dis Esophagus ; 33(10)2020 Oct 12.
Artículo en Inglés | MEDLINE | ID: mdl-32115648

RESUMEN

There is debate surrounding the appropriate threshold for lymph node harvest during esophagectomy in patients with esophageal cancer, specifically for those receiving preoperative radiation. The purpose of this study was to determine the impact of lymph node yield on survival in patients receiving preoperative chemoradiation for esophageal cancer. The National Cancer Database (NCDB) was utilized to identify patients with esophageal cancer that received preoperative radiation. The cohort was divided into patients undergoing minimal (<9) or extensive (≥9) lymph node yield. Demographic, operative, and postoperative outcomes were compared between the groups. Kaplan-Meier analysis with the log rank test was used to compare survival between the yield groups. Cox proportional hazards model was used to determine the association between lymph node yield and survival. In total, 886 cases were included: 349 (39%) belonging to the minimal node group and 537 (61%) to the extensive group. Unadjusted 5-year survival was similar between the minimal and extensive groups, respectively (37.3% vs. 38.8%; P > 0.05). After adjustment using Cox regression, extensive lymph node yield was associated with survival (hazard ratio 0.80, confidence interval 0.66-0.98, P = 0.03). This study suggests that extensive lymph node yield is advantageous for patients with esophageal cancer undergoing esophagectomy following induction therapy. This most likely reflects improved diagnosis and staging with extensive yield.


Asunto(s)
Neoplasias Esofágicas , Escisión del Ganglio Linfático , Neoplasias Esofágicas/patología , Neoplasias Esofágicas/cirugía , Esofagectomía , Esófago/patología , Humanos , Ganglios Linfáticos/patología , Estadificación de Neoplasias , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Tasa de Supervivencia
2.
J Med Primatol ; 47(1): 81-84, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-28671309

RESUMEN

Recrudescence of latent and dormant viruses may lead to overwhelming viremia in immunosuppressed hosts. In immunocompromised hosts, Simian virus 40 (SV40) reactivation is known to cause nephritis and demyelinating central nervous system disease. Here, we report SV40 viremia leading to fatal interstitial pneumonia in an immunosuppressed host following renal allotransplantation.


Asunto(s)
Huésped Inmunocomprometido , Enfermedades Renales/fisiopatología , Macaca mulatta , Enfermedades de los Monos/fisiopatología , Neumonía/fisiopatología , Infecciones por Polyomavirus/veterinaria , Virus 40 de los Simios/fisiología , Infecciones Tumorales por Virus/veterinaria , Animales , Enfermedades Renales/virología , Trasplante de Riñón/veterinaria , Enfermedades de los Monos/virología , Neumonía/virología , Infecciones por Polyomavirus/complicaciones , Infecciones Tumorales por Virus/complicaciones
3.
Am J Transplant ; 17(5): 1193-1203, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-27888551

RESUMEN

Costimulation blockade (CoB) via belatacept is a lower-morbidity alternative to calcineurin inhibitor (CNI)-based immunosuppression. However, it has higher rates of early acute rejection. These early rejections are mediated in part by memory T cells, which have reduced dependence on the pathway targeted by belatacept and increased adhesion molecule expression. One such molecule is leukocyte function antigen (LFA)-1. LFA-1 exists in two forms: a commonly expressed, low-affinity form and a transient, high-affinity form, expressed only during activation. We have shown that antibodies reactive with LFA-1 regardless of its configuration are effective in eliminating memory T cells but at the cost of impaired protective immunity. Here we test two novel agents, leukotoxin A and AL-579, each of which targets the high-affinity form of LFA-1, to determine whether this more precise targeting prevents belatacept-resistant rejection. Despite evidence of ex vivo and in vivo ligand-specific activity, neither agent when combined with belatacept proved superior to belatacept monotherapy. Leukotoxin A approached a ceiling of toxicity before efficacy, while AL-579 failed to significantly alter the peripheral immune response. These data, and prior studies, suggest that LFA-1 blockade may not be a suitable adjuvant agent for CoB-resistant rejection.


Asunto(s)
Abatacept/farmacología , Rechazo de Injerto/tratamiento farmacológico , Supervivencia de Injerto/inmunología , Memoria Inmunológica/inmunología , Trasplante de Riñón/efectos adversos , Antígeno-1 Asociado a Función de Linfocito/química , Linfocitos T/inmunología , Animales , Modelos Animales de Enfermedad , Tasa de Filtración Glomerular , Rechazo de Injerto/etiología , Rechazo de Injerto/patología , Supervivencia de Injerto/efectos de los fármacos , Memoria Inmunológica/efectos de los fármacos , Inmunosupresores/farmacología , Pruebas de Función Renal , Antígeno-1 Asociado a Función de Linfocito/metabolismo , Macaca mulatta , Complicaciones Posoperatorias , Linfocitos T/efectos de los fármacos , Linfocitos T/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA